13th Euro Abstracts reviewers independently selected trials, assessed their quality and extracted data. Meta-analysis of head-to-head trials was performed. RESULTS: Seven RCTs comparing CIC vs. BUD were identifi ed and included in the analysis. Comparisons of both interventions in 1:1 and 1:2 dose ratios were assessed in 3 and 4 trials, respectively. CIC as compared with BUD in 1:1 dose ratio was associated with signifi cant improvement in forced vital capacity (FVC) and peak expiratory fl ow (PEF) by spirometry (WMD = 0.09 [0.03; 0.14] and WMD = 19.00 [2.37; 35.63], respectively) as well as reduction in proportion of symptom-free days (p = 0.018). No statistically signifi cant differences between both drugs in 1:2 dose ratios were observed. CIC and BUD in either dose showed comparable effi cacy with respect to the risk of asthma exacerbation, improvement in symptoms of asthma and forced expiratory volume in 1 second (FEV1). CIC-treated patients experienced less upper respiratory tract infections than those treated with BUD in 1:1 dose ratio, however the difference was on the border of statistical signifi cance (RR = 0.65 [0.43; 0.99], NNT not signifi cant). There were no statistically signifi cant differences between CIC and BUD in either dose ratio with respect to risk of adverse events, adverse events related to study medication, pharyngitis and dysphonia. CONCLUSIONS: Ciclesonide provides an improvement in spirometric paramethers and reduction of asthma symptom-free days as compared to budesonide in 1:1 dose ratio, while no differences were noticed between CIC and BUD in 1:2 dose ratio. Safety profi le of ciclesonide seems to be comparable with budesonide. OBJECTIVES: Current asthma management recommendations are based on the level of asthma control rather than disease severity. The fi nancial impact associated with asthma control needs to be determined. The primary objective of this study was to estimate quality of life and health care costs according to the patients' level of asthma control in France and in Spain. METHODS: An observational retrospective bottom-up cost of illness study was conducted in adults patients with asthma. Investigators were general practitioners. Asthma control was evaluated using the validated auto-test Asthma Control Test (ACTTM) for a one month period and 2009 GINA's asthma control criteria for a three months period. Quality of life (QoL) was assessed using EQ-5D profi le. Costs (direct and indirect) were evaluated from a societal perspective. RESULTS: 794 patients (France: 391; Spain: 403) were enrolled in the fi rst quarterly wave of the survey. Based on the ACT, asthma was determined to be well-controlled (ACT ≥ 20) in 48.1% [IC 95%: 42.1%-54%] and 56.2% [IC95: 51.1%-61.2%] of French and Spanish patients respectively. In both countries, EQ-5D scores were 0.9 and 0.7 in well-controlled and not well-controlled patients respectively (P < 0.0001). Total costs of asthma were directly related to asthma control in both countries. The average cost (Euros/month/patient) of well-controlled asthma was c28 (±36) in France and c77 (±105) in Spain compared with c140 (±782) (p = 0.0009) and c252 (±380) (p < 0.0001) respectively for not well-controlled asthma. Similar associations were observed using the latest GINA's criteria. CONCLUSIONS: We found strong associations between asthma control level, costs and QoL in patients with asthma. Achievement of good clinical control of asthma may result in a signifi cant decrease of the economic burden of asthma and a better health status in adults. OBJECTIVES: The prevalence of asthma has been reported to be increasing for decades, but recent studies suggest a leveling off or even decrease in prevalence among children. The objective of this study was to assess the trends in anti-asthma medication use in Dutch children from 1998 until 2007. METHODS: From the PHARMO Record Linkage System, an administrative database network of outpatient pharmacies, hospitals, and other settings, including data of ~4 million individuals in defi ned areas of the The Netherlands, we assessed 1) the proportion of children aged 0-19 years with at least one dispensing for short (SABA) or long-acting β2-antagonists (LABA), inhaled glucocorticoids (ICS), fi xed dose combinations (FDC) of LABA and ICS or leukotriene receptor antagonists (LRTA) in the years 1998-2007 stratifi ed by age groups, 2) the proportion of users per type for each year and 3) the age distribution per medication type for the year 2007. RESULTS: Overall prevalence of anti-asthma medication use was approximately 7% and remained stable between 1998 and 2007. Prevalence was highest among children aged 0-1 years and declined with increasing age. Over time, the prevalence remained stable in all age groups, except for the youngest in which it increased from 10% in 1998 to 19% in 2007. Use of ICS and LABA declined over time (user proportions: −17% and −3%), against increased use of LABA-ICS FDC and LRTA (+15% and +3%). Children <6 years made up relatively large proportions of SABA and ICS users, while the older children were more dominant in the other medication types. CONCLUSIONS: This study provides a comprehensive overview of trends in anti-asthma medication use in children showing no overall change in prevalence over time. However, a change in type of medication was observed. OBJECTIVES: To compare the impact of different pharmacotherapies on the cost of exacerbation of COPD in public hospitals in Hong Kong. METHODS: This was a retrospective study comparing the cost of management of chronic obstructive pulmonary disease (COPD) in patients from a public hospital perspective in Hong Kong. Institutional ethics approval was obtained. The patients were above 65 years with a diagnosis of COPD of stage 3 or above based on the GOLD guideline. COPD was defi ned based on ICD-9-CM codes. Two cohorts of patients were included: 1) Those who received fl uticasone propionate and salmeterol, plus ipratropium bromide and salbutamol inhalation, and 2) Those who received ipratropium bromide and salbutamol, and beclomethasone inhalation. Patients were followed for 6 months before and after medications. The date one of the therapies started was the index date. RESULTS: A total of 75 patients were recruited over January to June 2008. All values are expressed as mean ± SD. The number of emergency room visits and cost of visits before and after the index date for both cohorts did not show a signifi cant difference (1.86 ± 2.5 days vs. 1.62 ± 1.93 days and HKD1061 ± 1442 vs. HKD924 ± 1102 for cohort 1, 1.15 ± 1.28 days vs. 1.02 ± 1.29 days and HKD657 ± 730 vs. HKD582 ± 735 for cohort 2, p > 0.1). There was a trend of reduction in hospitalization days and cost of stay before and after the index date for cohort 1 (although not reaching a signifi cant level) but not in cohort 2 (20.6 ± 28.4 days vs. 15.6 ± 18.8 days and HKD68162 ± 93875 vs. HKD51662 ± 66278 for cohort 1, 11.1 ± 13.5 days vs. 10.2 ± 13.2 days and HKD36730 ± 44604 vs. HKD33860 ± 43571 for cohort 2, p > 0.1).
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QUALITY OF LIFE AND ECONOMIC IMPACT OF ASTHMA CONTROL IN FRANCE AND SPAIN. FIRST RESULTS OF THE EU-COAST STUDY
Chouaid C 1 , Calvo Corbella E 2 , Com-ruelle L 3 , Brosa M 4 , Doz M 5 , Gueron B 6 1 Hôpital St Antoine, Paris, France; 2 Centro de Salud Universitario Pozuelo I. UAM., Madrid, Spain; 3 IRDES, Paris, France; 4 Oblikue Consulting, Barcelona, Spain; 5 CEMKA, Bourg La Reine, France; 6 GSK, London, England OBJECTIVES: Current asthma management recommendations are based on the level of asthma control rather than disease severity. The fi nancial impact associated with asthma control needs to be determined. The primary objective of this study was to estimate quality of life and health care costs according to the patients' level of asthma control in France and in Spain. METHODS: An observational retrospective bottom-up cost of illness study was conducted in adults patients with asthma. Investigators were general practitioners. Asthma control was evaluated using the validated auto-test Asthma Control Test (ACTTM) for a one month period and 2009 GINA's asthma control criteria for a three months period. Quality of life (QoL) was assessed using EQ-5D profi le. Costs (direct and indirect) were evaluated from a societal perspective. RESULTS: 794 patients (France: 391; Spain: 403) were enrolled in the fi rst quarterly wave of the survey. Based on the ACT, asthma was determined to be well-controlled (ACT ≥ 20) in 48.1% [IC 95%: 42.1%-54%] and 56.2% [IC95: 51.1%-61.2%] of French and Spanish patients respectively. In both countries, EQ-5D scores were 0.9 and 0.7 in well-controlled and not well-controlled patients respectively (P < 0.0001). Total costs of asthma were directly related to asthma control in both countries. The average cost (Euros/month/patient) of well-controlled asthma was c28 (±36) in France and c77 (±105) in Spain compared with c140 (±782) (p = 0.0009) and c252 (±380) (p < 0.0001) respectively for not well-controlled asthma. Similar associations were observed using the latest GINA's criteria. CONCLUSIONS: We found strong associations between asthma control level, costs and QoL in patients with asthma. Achievement of good clinical control of asthma may result in a signifi cant decrease of the economic burden of asthma and a better health status in adults.
PRS10 TRENDS IN ANTI-ASTHMA MEDICATION USE IN DUTCH CHILDREN FROM 1998 UNTIL 2007
Houweling LM, Penning FJ, Meijer WM PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands OBJECTIVES: The prevalence of asthma has been reported to be increasing for decades, but recent studies suggest a leveling off or even decrease in prevalence among children. The objective of this study was to assess the trends in anti-asthma medication use in Dutch children from 1998 until 2007. METHODS: From the PHARMO Record Linkage System, an administrative database network of outpatient pharmacies, hospitals, and other settings, including data of ~4 million individuals in defi ned areas of the The Netherlands, we assessed 1) the proportion of children aged 0-19 years with at least one dispensing for short (SABA) or long-acting β2-antagonists (LABA), inhaled glucocorticoids (ICS), fi xed dose combinations (FDC) of LABA and ICS or leukotriene receptor antagonists (LRTA) in the years 1998-2007 stratifi ed by age groups, 2) the proportion of users per type for each year and 3) the age distribution per medication type for the year 2007. RESULTS: Overall prevalence of anti-asthma medication use was approximately 7% and remained stable between 1998 and 2007. Prevalence was highest among children aged 0-1 years and declined with increasing age. Over time, the prevalence remained stable in all age groups, except for the youngest in which it increased from 10% in 1998 to 19% in 2007. Use of ICS and LABA declined over time (user proportions: −17% and −3%), against increased use of LABA-ICS FDC and LRTA (+15% and +3%). Children <6 years made up relatively large proportions of SABA and ICS users, while the older children were more dominant in the other medication types. CONCLUSIONS: This study provides a comprehensive overview of trends in anti-asthma medication use in children showing no overall change in prevalence over time. However, a change in type of medication was observed.
RESPIRATORY-RELATED DISORDERS -Cost Studies
PRS11 COST ANALYSIS OF DIFFERENT PHARMACOTHERAPIES IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE PUBLIC SECTOR OF HONG KONG
Lee KK 1 , Yu W 2 , Ko F 3 , Lee VW 3 , Chow DP 3 1 Monash University Kuala Lumpur Sunway Campus, Selangor Darul Ehsan, Malaysia; 2 Princess Margaret Hospital, Hong Kong, China; 3 Chinese University of Hong Kong, Hong Kong OBJECTIVES: To compare the impact of different pharmacotherapies on the cost of exacerbation of COPD in public hospitals in Hong Kong. METHODS: This was a retrospective study comparing the cost of management of chronic obstructive pulmonary disease (COPD) in patients from a public hospital perspective in Hong Kong. Institutional ethics approval was obtained. The patients were above 65 years with a diagnosis of COPD of stage 3 or above based on the GOLD guideline. COPD was defi ned based on ICD-9-CM codes. Two cohorts of patients were included: 1) Those who received fl uticasone propionate and salmeterol, plus ipratropium bromide and salbutamol inhalation, and 2) Those who received ipratropium bromide and salbutamol, and beclomethasone inhalation. Patients were followed for 6 months before and after medications. The date one of the therapies started was the index date. RESULTS: A total of 75 patients were recruited over January to June 2008. All values are expressed as mean ± SD. The number of emergency room visits and cost of visits before and after the index date for both cohorts did not show a signifi cant difference (1.86 ± 2.5 days vs. 1.62 ± 1.93 days and HKD1061 ± 1442 vs. HKD924 ± 1102 for cohort 1, 1.15 ± 1.28 days vs. 1.02 ± 1.29 days and HKD657 ± 730 vs. HKD582 ± 735 for cohort 2, p > 0.1). There was a trend of reduction in hospitalization days and cost of stay before and after the index date for cohort 1 (although not reaching a signifi cant level) but not in cohort 2 (20.6 ± 28.4 days vs. 15.6 ± 18.8 days and HKD68162 ± 93875 vs. HKD51662 ± 66278 for cohort 1, 11.1 ± 13.5 days vs. 10.2 ± 13.2 days and HKD36730 ± 44604 vs. HKD33860 ± 43571 for cohort 2, p > 0.1). CONCLUSIONS: A trend of reduction in hospital stay was demonstrated (although not statistically signifi cant) in patients after receiving combination therapy of fl uticasone propionate and salmeterol plus ipratropium bromide and salbutamol. This is consistent with earlier studies in other countries. a larger number of patients is required to prove the signifi cance of this fi nding.
